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A B S T R A C T   
Background: In 2018, tafenoquine was approved for malaria chemoprophylaxis. We evaluated all available data 
on the safety and efficacy of tafenoquine chemoprophylaxis. 
Methods: This systematic review followed the PRISMA guidelines and was registered on PROSPERO 
(CRD42019123839). We searched PubMed, Embase, Scopus, CINAHL and Cochrane databases. Two authors 
(JDM, PS) screened all papers. 
Results: We included 44 papers in the qualitative and 9 in the quantitative analyses. These 9 randomized, 
controlled trials included 2495 participants, aged 12–60 years with 27.3% women. Six studies were conducted in 
Plasmodium spp.-endemic regions; two were human infection studies. 200 mg weekly tafenoquine and higher 
dosages lead to a significant reduction of Plasmodium spp. infection compared to placebo and were comparable to 
250 mg mefloquine weekly with a protective efficacy between 77.9 and 100% or a total risk ratio of 0.22 (95%- 
CI: 0.07–0.73; p = 0.013) in favour of tafenoquine. Adverse events (AE) were comparable in frequency and 
severity between tafenoquine and comparator arms. One study reported significantly more gastrointestinal 
events in tafenoquine users (p ≤ 0.001). Evidence of increased, reversible, asymptomatic vortex keratopathy in 
subjects with prolonged tafenoquine exposures was found. A single, serious event of decreased macular sensi-
tivity occurred. 
Conclusion: This systematic review and meta-analysis of trials of G6PD-normal adults show that weekly tafe-
noquine 200 mg is well tolerated and effective as malaria chemoprophylaxis focusing primarily on Plasmodium 
falciparum but also on Plasmodium vivax. Our safety analysis is limited by heterogenous methods of adverse 
events reporting. Further research is indicated on the use of tafenoquine in diverse traveller populations.   
1. Introduction 
Malaria caused 228 million infections and 405,000 deaths in 2019 
[1]. Persons living in endemic areas are at high risk of infection, as are 
travellers visiting such areas [2]. Antimalarial drugs constitute an 
important pillar of malaria prevention, together with individual mea-
sures against mosquito bites [2]. Since malaria chemoprophylaxis is 
generally taken by healthy travellers, it is important that such regimens 
are effective, safe, well tolerated, and offer convenient dosing schedules 
ensuring good adherence [3]. [4,5]. 
Chemoprophylaxis against malaria has long been dominated by 
drugs active only against the asexual blood stages of the plasmodia 
responsible for the acute clinical attack. These suppressive agents alone 
do not prevent the latent malaria (typical of Plasmodium vivax and 
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Plasmodium ovale) due to dormant hepatic stages called hypnozoites that 
can occur in the weeks and months following travel [6]. In contrast, 
causal prophylaxis, kills all hepatic plasmodia either in the primary liver 
phase or the dormant liver phase “hypnozoites”. In this way, causal 
chemoprophylaxis prevents both acute and delayed malaria attacks 
during and after travel. 
In 2018, a novel antimalarial drug, tafenoquine, was approved in the 
US and Australia [7,8]. Tafenoquine is an 8-aminoquinoline from the 
late 1970s [9,10]. Its main advantage compared to other antimalarials is 
its effects on all human malaria parasite stages and species at thera-
peutic dosing (Fig. 1) [7,11]. Use in anti-relapse therapy places tafe-
noquine alongside another 8-aminoquinoline, primaquine, which for 
over 60 years had been the only effective therapy against latency in the 
hypnozoite-bearing species [7,12]. Even though, primaquine is consid-
ered a robust anti-relapse therapy and radical cure for those infections, 
its safe and efficacious use as a causal chemoprophylactic agent was 
demonstrated but not widely practiced [13,14]. Unlike primaquine, 
tafenoquine has a prolonged half-life of 12–17 days [14–16] enabling 
weekly dosing for chemoprophylaxis [14]. As with primaquine, tafe-
noquine comes with potentially dangerous haemolytic toxicity in 
G6PD-deficient patients and thus requires G6PD testing prior to use. 
Pregnancy contraindicates tafenoquine use and tafenoquine is not yet 
proven safe as chemoprophylaxis for those aged <18 years, [17]. The 
duration of chemoprophylactic dosing is limited to 6 months [18]. 
Tafenoquine represents an important advance in the prevention of 
travellers’ malaria in promising improved adherence and as a solitary 
chemoprophylactic agent preventing both acute and delayed attacks of 
malaria. 
This systematic review evaluated several randomized, double-blind, 
placebo-controlled, and/or active controlled studies eligible for a sub-
sequent meta-analysis (Table 1). Reviews have already been conducted, 
addressing the safety and efficacy of tafenoquine [19,20]. In contrast to 
these studies, this systematic review scrutinizes efficacy and safety data 
for primary chemoprophylaxis only and includes studies, that have not 
previously been analysed in a meta-analysis. 
2. Methods 
We conducted the systematic review according to the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
guidelines [21]. Details of the protocol for this systematic review were 
registered on PROSPERO (CRD42019123839) [22]. 
The electronic literature search included all past studies until June 
6th, 2020 using searches of the electronic databases PubMed, Embase, 
Scopus, CINAHL, and Cochrane Library. The search query combined 
tafenoquine with several synonyms (including WR238605 and etaquine) 
to identify all potential studies and was developed by JM and PS (Ap-
pendix A). After duplicates were removed by JM using Endnote [23], 
two authors (JM and PS) screened independently all titles and abstracts 
according to inclusion and exclusion criteria (Table 2). After the 
screening, a full-text assessment was performed by two authors (JM and 
PS) for eligibility. At any selection step, disagreements between re-
viewers were resolved by consensus. Additional records were obtained 
by contacting study authors and/or study sponsors. 
For the meta-analysis, we included randomized clinical trials only. 
However, for the qualitative assessment, we used other types of records, 
such as pre-specified analysis plans (Fig. 2). Concerning chemopro-
phylactic efficacy, we only included studies, that administered tafeno-
quine before malaria exposure. Safety data were extracted when drug 
intake duration was longer than one week. This duration was chosen to 
best display adverse events that can occur during prolonged use, rather 
than short use as in radical cure or anti-relapse therapy. The records 
were included independent of participant characteristics (e.g. naïve/ 
non-naïve, age, sex) outcome measurement method, length of follow-up, 
published language, publication date, as well as tafenoquine dosage and 
intake frequency. 
Two authors (PS and JM) conducted data extraction according to the 
DECiMAL guide [24]. While one reviewer (JM) extracted data from 
included studies, the second one (PS) checked all extracted data. Dis-
agreements were discussed and resolved by consensus. 
The extracted information is detailed in Tables 1, 3–7, appendix B 
Fig. 1. Sites of tafenoquine action in the Plasmodium species human life cycle. Adapted from Schlagenhauf, Funk: PDQ Traverlers’ Malaria.  
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and E. For the safety analysis, serious and non-serious adverse events, 
and laboratory results from published records were extracted. Adverse 
events were extracted as a total and as individual symptoms; these in-
dividual symptoms were then grouped according to the Medical Dic-
tionary for Regulatory Activities (MedDRA® version 22.0). When a 
symptom could be categorized into several groups, it was assigned to the 
most suitable group. When two or more Plasmodium species were 
detected, the combined incidence was extracted for meta-analysis. 
For the efficacy data, meta-analyses were performed. The effect of 
prophylaxis was expressed as risk ratios (RR) with 95% confidence in-
tervals (CIs) comparing the incidence of parasitaemia in the group 
receiving tafenoquine prophylaxis with the placebo or mefloquine 
group. Pooled analyses were conducted with a random effects model 
using logit transformed proportions, with subsequent back- 
transformation to the original scale. To avoid numerical issues, zero 
events adjustments were applied by adding a constant of 0.5 for 
computing both the proportion and the corresponding sampling vari-
ance for studies with zero events in at least one cell. 
Results were visualised in forest plots with the estimate and 95% CIs 
for the pooled RR given by the black diamond. The RR of each trial and 
95% Cis are indicated by individual squares and horizontal bars. The 
size of the square is proportional to the weight given to each individual 
trial by random effects model pooling the outcomes. The. Additionally, 
Cochrane’s Q-test for heterogeneity with corresponding p-value and I2 
for the total heterogeneity over the total variability were computed. A p- 
value of <0.05 of the heterogeneity tests was indicative of heteroge-
neous outcomes. All meta-analyses were performed in the R system for 
statistical computing (version 4.0.0), using the package metafor (version 
2.4.0) [25]. 
The risk of bias was assessed by two authors (PS and JM) using the 
revised Cochrane risk of bias tool for randomized trials (RoB 2) [26]. 
According to RoB 2, missing outcome data of >5% were considered as 
high. Discrepancies were discussed and resolved by consensus. 
3. Results 
A total of 44 publications were selected for qualitative analysis, of 
which 9 were included for quantitative analysis of efficacy (n = 8) and 
safety (n = 7) (Fig. 2). After full text assessment of 82 records, one 
additional record for inclusion was identified: An Australian New 
Table 1 
Overview study characteristics. AC = Active Comparator (250 mg Mefloquine), BC = bicentric, DB = Double-Blind, HC = Human Challenge Study, MC = monocentric, 
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Table 2 
Eligibility criteria for screening and full-text analysis.   
Criteria for inclusion in qualitative and/or quantitative analysis Criteria for inclusion in discussion Criteria for exclusion 
Subjects Primary chemoprophylaxis of tafenoquine regarding safety, 
tolerability and/or efficacy 













•in vitro studies 
•non-malarial diseases   
Studies including single dosages concerning: 
•pharmacokinetics 
•drug-drug interaction 
•sex differences    
Animal based studies (in vivo) if other inclusion criteria for 
qualitative and/or quantitative analysis are met  
Record 
types 
•clinical trial, RCT 
•clinical trial protocol 
•human challenge studies 
•no study phase restriction 
•trial registries 
•reviews 
•letters to the editor 





No language exclusion    
Studies with other topics but same study population as trials 
included for qualitative and/or quantitative    
Fig. 2. Flow chart for the selection of records. “Records for discussion” are records, that were excluded but might be useful for the discussion part of this paper. All 
excluded records were categorized according to eligibility criteria. One study can be present in two or more categories within a list, except when tafenoquine was no 
major subject, there was non-malarial subject, it was a review protocol, the article/study was not available or there was only redundant information already covered 
in an included record. For example, when tafenoquine was no major subject, it was only categorized into “tafenoquine is no major subject”. The records listed in “full- 
text articles included for qualitative synthesis” are only mentioned ones per category. 
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Zealand Clinical Trials Registry record, which was the source of the 
included record from the International Clinical Trials Registry Platform 
[27]. Another 18 records were included after correspondence with study 
authors and GlaxoSmithKline (GSK). 
All 9 studies included for quantitative analysis were randomized 
controlled studies. The duration of drug intake was between 1 day and 6 
months, while the follow-up monitoring lasted between 9 weeks and 9 
months. Overall, 2495 participants (female n = 669/2449; 27.3%) were 
randomized in all 9 studies, while 2274 participants (female n = 622/ 
2329; 26.7%) were eligible for efficacy and 2049 participants were 
eligible (female n = 452/2039; 22.2%) for safety analysis. Since the 
proportion of sex was only given once for the intend-to-treat or per- 
protocol population per study, the number differs slightly when the 
other population was used for analysis. Different participant inclusion 
and exclusion criteria were used (Appendix B). All participants with a 
glucose-6-phosphate dehydrogenase (G6PD) deficiency, pregnancy, 
breastfeeding, and clinically relevant abnormal laboratory or physical 
examination were excluded per investigation protocols. 
Most of the studies were monocentric; only Leary at al. conducted a 
two-centre study (Table 1) [28]. The study authors performed either 
intention-to-treat, modified intention-to-treat, and/or per-protocol 
population analyses. Study interventions varied from oral single dos-
ages (600 mg tafenoquine base), only loading dosages (25–400 mg 
tafenoquine base, daily for 3 days) to weekly (25–400 mg tafenoquine 
base), and monthly dosages (400 mg tafenoquine base). Active control 
arms were always weekly 250 mg mefloquine (Table 3). Definitions of 
efficacy outcome points always included newly detected positive blood 
smears during prophylactic study phase except in McCarty et al., 2018 
where qPCR was employed for malaria detection [29]. All studies 
included for efficacy analysis screened all participants periodically, 
independently of symptoms. Safety outcome points varied greatly 
among the included studies (Table 4). All included RCT’s evaluated 
adverse events, but not all were included in our safety analysis, since the 
duration of drug intake in 2 RCT’s was shorter than a week [30,31]. The 
timing of outcome measures varied between daily and monthly evalu-
ations; they also varied within a study for different outcome parameters. 
Follow-up time depended on the endemic Plasmodium species; being 
prolonged if Plasmodium vivax were present (Table 1). 
Bias assessments were done for each safety and efficacy analysis 
shown in Figs. 3–5. The detailed bias assessment is described in Ap-
pendix C. 
Efficacy analysis: Eight studies were analysed for efficacy (Table 5). 
Seven of them compared tafenoquine to placebo while Nasveld et al., 
2010 only used an active comparator [32]. An active comparator was 
also used by Hale et al., 2003 and Stoute et al., 2017 (Table 3) [33,34]. 
Since placebo arms are needed for calculating protective efficacy, the 
published paper by Nasveld et al., 2010 was followed by Dow et al., 
2014, a retrospective study to assess protective efficacy using an esti-
mated malaria attack rate [35]. While six studies were RCT’s conducted 
in endemic regions exposed to malaria infection, two were human 
challenge studies using intravenous injection of viable 
P. falciparum-infected erythrocytes or viable sporozoites from feeding 
mosquitos (Table 1) [29,31]. Most studies described an exposure to 
P. falciparum, while two studies also stated P. vivax as an additional 
possible infectious agent. 
While sex differences were not analysed in all included RCT’s, Hale 
et al., 2003 detected a significant interaction between treatment efficacy 
and body weight (P < 0.001). Blood smears were more likely to be 
positive among heavier subjects [33]. 
Tafenoquine vs. placebo: Most analysed studies favour tafenoquine 
over placebo for malaria chemoprophylaxis. Three studies, however, did 
not show evidence for a reduction in acquired malaria infection (Fig. 6). 
Two of those three studies only administered tafenoquine during a 
narrow time frame at the start with 600 mg tafenoquine in total 
(Table 3) [30,31,34,36]. After correspondence with GSK about the high 
failure rate reported by the third one, Stoute et al., 2017, they explained 
that “there were issues identified with the quality of the slide reading, 
resulting in false positives” [36]. 
For the currently approved tafenoquine dosages of 200 mg weekly, 
we calculated a total RR of 0.22 (95%-CI: 0.07–0.73; p = 0.013) in 
favour of tafenoquine (Fig. 6) and for all included dosages above 200 mg 
independent of frequency a RR of 0.20 (95%-CI: 0.10–0.39; p < 0.0001). 
Besides Stoute et al., 2017, the protective efficacy of tafenoquine for the 
ones that favour tafenoquine ranged between 85.6% and 100%, while 
Stoute et al., 2017 calculated a protective efficacy of 77.9% (Table 5) 
[34]. Higher doses of tafenoquine resulted in protective efficacies of 
89% (400 mg, weekly) and 97% (400 mg, monthly), respectively, and 
RR of 0.12 (95%-CI: 0.05–0.25) and 0.03 (95%-CI: 0.00–0.23), respec-
tively (Table 5, Fig. 6). 
Both human challenge studies did not report any protective efficacy, 
but tafenoquine drug failures of 0% and 25% in McCarthy et al., 2018 
and Brueckner et al. respectively (Table 5) [29,31]. Both performed a 
single challenge on day 3 and day 1 after the last tafenoquine dosage, 
respectively [29,31]. 
Tafenoquine vs. mefloquine: Three studies used mefloquine as an 
active comparator (Table 3) [32–34]. Hale et al., 2003 states, that their 
comparison of tafenoquine to mefloquine could only be descriptive, due 
to low power. Nevertheless, the protective efficacy of tafenoquine and 
mefloquine were similar (Table 5). The retrospective study conducted by 
Dow et al., 2014 and the clinical study by Stoute et al., 2017 did not 
show evidence for a difference in protective efficacy by tafenoquine or 
mefloquine [34,35]. Our RR analysis resulted in a pooled RR of 0.95 
(95%-Cl: 0.87–1.04, p = 0.26), however, does support those numbers 
and shows no evidence for favouring towards tafenoquine or mefloquine 
(Fig. 7). 
Safety analysis: Seven studies were analysed for safety (Table 1). Six 
of them compared tafenoquine to placebo while one used an active 
comparator (Table 1) [33,34]. As for the efficacy analysis, our safety 
analysis only included dosages from 200 mg and higher regardless of the 
frequency but with a duration of at least one week. 
Studies included in the safety analysis reported comparable adverse 
event rates between prophylaxis groups, with some exceptions. Walsh 
et al., 2004 reported a significant higher number of gastrointestinal 
complaints among tafenoquine recipients (p ≤ 0.001, Fisher’s exact test; 
placebo n = 24/101, 23.8%; tafenoquine monthly 400 mg n = 74/104, 
71.2%; Fig. 8, Appendix E) than among placebo recipients [37]. Leary 
et al., 2009 noted a higher incidence of nausea in the tafenoquine than in 
the placebo group, but a higher incidence of headache in the placebo 
than in the tafenoquine group (Fig. 9) [28]. Furthermore, Leary et al. 
Table 3 
Study dosages. Loading dose always was always done except “single dose” is 
mentioned. A Loading dose included the displayed dosage on day one, two and 
three.  
Study Study arms 
tafenoquine mefloquine placebo 
Lell 2000 25 mg, 50 mg, 100 mg, 200 mg 





200 mg (loading dose only with 
weekly placebo), 200 mg (weekly), 
400 mg (weekly) 
– weekly 





Walsh 2004 400 mg (monthly) – monthly 
Leary 2009 200 mg (weekly) – weekly 
Nasveld 
2010 
200 mg (weekly) 250 mg 
(weekly)  





600 mg (single dose) – Single dose 
McCarthy 
2018 
200 mg (weekly) – weekly  
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reported five cases of “treatment emergent myalgia/intercostal myalgia 
in tafenoquine persons, compared with none in the placebo group” with 
abnormal creatinine phosphokinase (CPK) in two of them [28]. Shanks 
et al., 2001 described a higher incidence of gastrointestinal adverse 
events in participants who received 400 mg weekly as well but also more 
dermatological events across all tafenoquine arms than in the placebo 
group [38]. Stoute et al., 2017 shows a higher incidence trend in back 
pain among tafenoquine recipients than in placebo and mefloquine re-
cipients (Fig. 9) [34]. Nasveld et al., 2010 observed no evidence for a 
difference in any adverse events between tafenoquine and mefloquine 
groups, regardless of whether they were related to study drug or not 
[32]. In all studies, except for one syncope, no cardiac adverse events 
and no evidence for ECG changes were reported. 
Study discontinuation: While subject withdrawal across studies 
were zero to 25.5% in any tafenoquine study arm (placebo 0.0–11.5%; 
mefloquine 2.0%–5.6%), subject withdrawal due to adverse events 
ranged between zero to 9.7% (placebo: 0.00–5.1%; mefloquine: 
0.0–1.9%) (Table 6). Even though Hale et al., 2003 reported study 
discontinuation across all study arms (83/509, 16.31%), they were not 
included since no data per study arm was provided by the authors [34]. 
Serious adverse events: A total of 24/1000 (2.4%) serious adverse 
events were reported in all tafenoquine groups using dosages of 200 mg 
or higher, 2/309 (0.6%) in the mefloquine groups and 18/400 (4.5%) in 
the placebo groups (Table 6). Only one serious adverse event in the 
tafenoquine arm, but none in the mefloquine and placebo arms, was 
considered possibly related to the study drug. That possibly related 
serious adverse event was a decrease in macular sensitivity recorded by 
Leary et al., 2009 [28]. One serious adverse event reported by Hale 
et al., 2003 occurred in a non-randomized participant, which is why that 
participant was not considered for the safety analysis [33]. Nasveld 
et al., 2010 and Shanks et al., 2001 did not explicitly mention any 
serious adverse events. However, for Shanks et al., 2001, we extracted 
them from the clinical study report, which was provided by GSK [32, 
38]. 
Laboratory adverse events: Most laboratory values, if abnormal, 
showed only minor and transient changes. Those that showed differ-
ences were haemolytic parameters, bilirubin, liver enzymes, kidney 
parameters and methaemoglobin (Table 7). 
Changes in haemoglobin and haemolytic parameters were generally 
more common in tafenoquine recipients, however, no evidence for a 
difference between arms were reported [28,29,32–34,38]. Increased 
bilirubin values were only mentioned by two studies, mainly detected in 
Table 4 
Differences in adverse events reporting. NS = not specified, NR = not reported, S = solicited, US = unsolicited.  
Study Adverse events reporting AE assessment frequency Solicited, 
unsolicited 
Definition of serious adverse events by study authors 
Lell 2000 “The volunteers were urged to report to 
investigators if any medical problem occurred." 
Once weekly S NR  
Shanks 
2001 
“On a weekly basis (done when the subjects 
received their medication), volunteers were 
questioned regarding adverse events, a malarial 
blood smear was performed, and a review of 
concomitant medication was performed.” 
Once weekly S A serious adverse drug event was any event that was 
fatal, life threatening, permanently disabling, 
required subject hospitalization, or was a congenital 
abnormality, cancer, or overdose. In addition any 
event which the study staff regarded as serious or 
that suggested any significant hazard, 
contraindication, side effect or precaution that might 
have been associated with the use of the drug was to 
be reported as a serious event  
Hale 2003 “[…] complaints or symptoms were reported to the 
study-team physicians. Subjects with physical 
complaints were examined by a study physician 
the next day or on an emergent basis, as needed.” 
3 times a week S NR  
Walsh 2004 “Adverse events were recorded […] according to a 
predefined coded checklist of the most commonly 
expected AEs.” 
Daily during the 3-day loading 
dose and then at approximately 
24 h after each dose. 
S Serious AEs were defined as those that required 
hospital admission.  
Leary 2009 “Adverse event reporting, pregnancy testing, and 
concomitant medications review were conducted 
at screening, weekly throughout the dosing period, 
and at follow-up.” 
Once weekly. S Serious adverse events were defined as events that 
resulted in death, were life-threatening, required 
hospitalization, prolongation of an existing 
hospitalization, or resulted in incapacity or 
disability. The protocol defined clinically significant 
renal and ophthalmic events as serious AEs to 
facilitate expedited reporting.  
Nasveld 
2010 
“Adverse events monitoring was supplemented by 
review of subjects’ medical records. Disclosure of 
adverse events was elicited by the investigator 
asking the subject the nonleading question, " Do 
you feel differently in any way since starting the 
new treatment?” A Study physician assessed the 
level of relationship of any adverse event on the 
basis of the subject’s response and any temporal 
association and/or known adverse events as mild 
(not affecting daily activities), moderate (with 
some interference in daily activities), and severe 
(when daily duties could not be completed). A 
causal relationship to the study drug was judged by 
the physician to be not related, unlikely, suspected, 
or probable.” 
Prophylactic phase: At loading 
stage, week 4, 8, 16 and 26. 
Follow-up phase: Week 2 and 
12 
S NR  
Stoute 2017 NR NR S NR  
Brueckner 
1998 
Volunteers were questioned periodically for 
symptoms 
Periodically. S NR  
McCarthy 
2018 
“Safety assessment included evaluation of AEs, AEs 
of special interest (AESI), physical examination, 
vital signs, clinical laboratory measurements […] 
and standard 12-lead ECGs (at screening only).” 
On days 4–9, 11–12 and 14–16. S NR   
J.D. Maier et al.                                                                                                                                                                                                                                 
Travel Medicine and Infectious Disease 39 (2021) 101908
7
tafenoquine arms, but significant differences between arms were not 
reported [29,32]. Elevated alanine aminotransferase (ALT) levels were 
reported by two studies, they were more common in tafenoquine arms, 
mostly transient and not associated with any symptoms. The exception 
was one participant, in which high ALT levels were caused by a chronic 
hepatitis B infection [33,37]. Three studies described elevated serum 
creatinine values, even though they were generally more seen in tafe-
noquine arms, no significant differences were reported [28,32,37]. 
Three studies reported increased methaemoglobin values in tafenoquine 
arms compared to placebo [32,37,38]. 
Ophthalmologic adverse events: Ophthalmological adverse events 
were reported by three studies [28,32,34]. While Nasveld et al., 2010 
and Leary et al., 2009 did additional eye examinations, Stoute et al., 
2017 only reported conjunctivitis as an adverse event (placebo n =
13/101; 12.9%, tafenoquine n = 12/104; 11.5%, mefloquine n = 7/101; 
6.9%). Nasveld et al., 2010 only assessed a subgroup (77 on tafenoquine, 
21 on mefloquine) for ophthalmic adverse events. They detected a high 
proportion of vortex keratopathy (corneal deposits) in tafenoquine re-
cipients only (n = 69/74; 93.2%; mefloquine n = 0/21; 0.0%), however, 
these changes were not associated with any visual disturbances. After 
one year of follow-up, every vortex keratography had dissolved [32]. 
The ophthalmologic adverse events were one of Leary et al., 2009’s 
primary endpoint. They did several ophthalmological tests, which yiel-
ded no differences in night vision, macular function, contrast visual 
acuity, colour vision, peripheral visual field, or retinal morphology. 
However, Leary et al., 2009 observed a non-significant newly occurring 
corneal deposits in tafenoquine users (n = 15/60, 25.0%) versus placebo 
group (n = 4/25, 16.0%) (p = 0.5683, Fisher’s exact test). While in 14 
tafenoquine receiving participants, corneal deposits resolved within 12 
weeks of onset, all 4 persons who received placebo, corneal deposits 
resolved within 6 weeks of onset. All corneal deposits resolved within 24 
weeks post-dosing. One tafenoquine recipient had a mild decrease in 
macular sensitivity, which was considered to be possibly related to study 
drug and was withdrawn from the study, this mild decrease resolved 
spontaneously. Retinal abnormalities were detected in both study arms 
once (tafenoquine and placebo). A single area of retinal hyperpigmen-
tation in a tafenoquine recipient was detected, which did not change 
after 11 months cessation of therapy. The retinal abnormality in the 
placebo recipient resolved within 2 months [28]. 
Nervous system and psychiatric adverse events (AE): No study 
Fig. 3. Risk of bias for included studies concerning efficacy and studies with intention-to-treat analyses.  
Fig. 4. Risk of bias for included studies concerning efficacy and studies with per-protocol analyses.  
J.D. Maier et al.                                                                                                                                                                                                                                 
Travel Medicine and Infectious Disease 39 (2021) 101908
8
reported evidence for differences in nervous system AE or psychiatric AE 
between tafenoquine, placebo, and/or mefloquine groups (Figs. 8 and 
9). However, the study published by McCarthy et al., 2018 with 16 
participants reported more than twice as many nervous system AE in the 
placebo group than in the tafenoquine group (headache n = 4/4; 100.0% 
vs. n = 4/7; 57.1%, hypoesthesia n = 1/4; 25% vs. n = 0/0; 0.0%, 
respectively) [29]. Additionally, Leary et al., 2009 also reported more 
nervous system AE in the placebo group compared to the tafenoquine 
group (especially headache n = 21/39; 53.8% vs. n = 29/81; 35.8%, 
respectively) [28]. 
4. Discussion 
This systematic review and meta-analysis assessed all available re-
cords to determine the efficacy and safety of tafenoquine as a chemo-
prophylactic drug against malaria. Tafenoquine chemoprophylaxis 
significantly protects from P. falciparum and possibly P. vivax infections 
with the approved dosage of weekly 200 mg. An adverse event incidence 
comparable to placebo or to mefloquine comparator was considered 
consistent with good safety and tolerability of tafenoquine chemopro-
phylaxis. We found an increased risk of gastrointestinal adverse events 
in tafenoquine arms and one study involving 6 months of dosing 
detected a significant increase in mild and reversible vortex keratog-
raphy. Given the limited number of participants in the trials evaluated 
Fig. 5. Risk of bias for included studies concerning safety and studies with intention-to-treat analyses.  
Table 5 
Overview of analysed study arms including duration of drug administration and reported protective efficacy. Loading doses were always done if “once” is not 
mentioned and they were done on day one, two and three with the mentioned dosages. ITT = intention-to-treat, mITT = modified intention-to-treat, pp = per-protocol, 
taf = tafenoquine, mef = mefloquine, *protective efficacy calculated by Dow et al. 2014.   






amount and frequency of drug 
administration 
duration of tafenoquine 
administration 
protective efficacy in 
% (95% CI) 
Lell 2000 410 5 pp 200 mg, only loading dose (taf) 3 days (primary endpoint at 
day 56) 
100 (0, 100) 
3 days (secondary endpoint 
at day 77) 
100 (71, 100) 
Shanks 2001 235 4 mITT 200 mg, weekly (taf) 13 weeks 86 (73, 93) 
400 mg, only loading dose (taf) 68 (53, 79) 
400 mg, weekly (taf) 89 (77, 95) 
Hale 2003 509 6 mITT 200 mg, weekly (taf) 12 weeks 85.6 (76.2, 91.6) 
250 mg, weekly (mef) 85.7 (71.9, 93.3) 
Walsh 2004 205 2 mITT 400 mg, monthly (taf) 26 weeks 97 (82, 99) 
Nasveld 2010/ 
Dow 2014* 
651 2 pp/ITT 200 mg, weekly (taf) 26 weeks 100 (93, 100)* 
250 mg, weekly (mef) 100 (79, 100)* 
Stoute 2017 300 3 pp 200 mg, weekly (taf) 24 weeks 77.9 (59.7, 88.2) 
250 mg, weekly (mef) 56.8 (32.5, 72.9)  
drug failure (%) 
Brueckner 1998 6 2 ITT 600 mg, once (taf) 1 day 25 
McCarthy 2018 16 2 ITT 200 mg, weekly (taf) 2 weeks 0  
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here, we may not rule out relatively infrequent or rare serious adverse 
events detectable only in larger post-marketing studies. 
Regarding efficacy, our analysis shows that the currently approved 
prophylactic dosage of weekly 200 mg tafenoquine significantly protects 
against P. falciparum (RR = 0.22; 95%-CI: 0.07–0.73; p = 0.013). In two 
of these analysed studies, a protection against P. vivax was also seen. 
One study did not show any advantage in taking tafenoquine for 
chemoprophylaxis, but an Independent Data Monitoring Committee 
(IDMC) identified numerous false positive malaria microscopy readings. 
That trial cannot therefore be considered an accurate measurement of 
the chemoprophylactic efficacy of tafenoquine [36]. However, we 
included the afore-mentioned study to give a complete view of tafeno-
quine chemoprophylaxis and to avoid publication bias. Beside weekly 
200 mg tafenoquine, other dosages also showed statistically 
Fig. 6. Forest plot of tafenoquine versus placebo. Pooled RR for 200 mg tafenoquine = 0.22 (95%-CI: 0.07–0.73; p = 0.013); Pooled RR for all tafenoquine doses =
0.20 (95%-CI: 0.10–0.39; p < 0.0001). For Lell et al., 2000, only the primary endpoint for efficacy (day 56) was analysed, thus, only that data is displayed here. 
Fig. 7. Forest plot of tafenoquine vs mefloquine. Pooled RR = 0.95 (95%-CI: 0.87–1.04; p = 0.26).  
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significance: monthly and weekly 400 mg tafenoquine as well as a 400 
mg loading dose (400 mg 3 times over 3 days) for 13 weeks with a 
follow-up of 4 weeks in a P. falciparum endemic region; whereas a 200 
mg tafenoquine loading dose (200 mg, 3 times over 3 days) and a single 
600 mg dose did not yield a significant protective effect (Fig. 6). No 
evidence for a difference in efficacy between tafenoquine and meflo-
quine was detected. However, the compared populations with 655 and 
298 participants, respectively, are too small to make a definitive 
conclusion with regard to the non-inferiority of efficacy of one in regard 
to the other. Nonetheless, tafenoquine might be considered more often 
Fig. 8. Overview of all reported adverse events per 100 participants grouped with MedDRA® terms. The bars represent the numbers of AE and the labelled x-axis 
gives the participant range. Groups with less than 5% as well as the MedDRA® group “injury, poisoning and procedural complications” are not displayed. Due to 
differences in adverse events reporting, comparisons between absolute number of adverse events should only be made within a study. All AE were counted, therefore 
one person could have more than one headache. Nasveld et al., 2010, Leary et al., 2009, Stoute et al., 2017 and Shanks et al., 2001 only published adverse events 
when they occurred in at least 5% of the subjects in any treatment group, serious adverse events were an exception [28,32,34,38]. 
Fig. 9. Overview of all reported adverse events per 100 participants, grouped in MedDRA® terms with colour. The bars represent the numbers of AE and the labelled 
x-axis gives the participant range. AE with less than 5% as well as “injury” and “others” are not displayed. Due to differences in adverse events reporting, comparisons 
between absolute number of adverse events should only be made within a study. All AE were counted, therefore one person could have more than one headache. 
Nasveld et al., 2010, Leary et al., 2009, Stoute et al., 2017 and Shanks et al., 2001 only published adverse events when they occurred in at least 5% of the subjects in 
any treatment group, serious adverse events were an exception [28,32,34,38]. (For interpretation of the references to colour in this figure legend, the reader is 
referred to the Web version of this article.) 
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as chemoprophylaxis if future safety data and a lower intake frequency 
support the use of tafenoquine over mefloquine. 
Our initial goal was to provide a meta-analysis of safety, but this was 
not feasible as individual safety data were not available. According to 
our safety analysis, gastrointestinal disorders were the most frequent 
adverse events (Fig. 9). A significantly higher occurrence of adverse 
events in the tafenoquine arms was only reported in one study for 
gastrointestinal disturbances and in another for vortex keratopathy. 
Even though some adverse events trended higher, relatively small study 
populations limited statistical power and inference. The frequency of 
discontinuation of dosing varied greatly but was mostly low, especially 
considering the relatively long durations involved in these trials (Ta-
bles 5 and 6). The trial from western Kenya reported by Shanks et al., 
2001, however, seemed to have had a relatively high discontinuation 
rate not addressed by those authors. Nevertheless, no evidence for a 
difference in study discontinuation between arms was reported in any 
trial. Since some of the trials employed military personnel as subjects, 
where a culture of discipline typically occurs, an expectation of similarly 
good adherence among more ordinary travellers should be regarded 
with some caution. Nonetheless, weekly dosing should favour good 
adherence. 
Ophthalmological adverse events are important in safety assessments 
of tafenoquine because Nasveld et al., 2010 detected vortex keratopathy 
events in most subjects exposed to tafenoquine chemoprophylaxis for 6 
months. Leary et al., 2009 [28]. Did a thorough study of ophthalmic 
safety over a prolonged period and reported a trend towards vortex 
keratopathy. Neither trial detected visual disturbances. Other 
ophthalmic safety studies were conducted employing other dosing reg-
imens [39–42]. Among those, Warrasak et al., 2018 [40] showed 400 mg 
daily TQ for 3 days caused mild vortex keratopathy. However, that 
ophthalmic safety assessment was inadequately statistically powered 
[40]. Tafenoquine causing vortex keratography may be apparent but is 
not yet definitive due to differences in ophthalmologic assessment 
methods and variable exposure to UV light depending on study location 
[28,43]. Vortex keratopathy is known to be associated with several 
drugs which are taken over a longer period (e.g. amiodarone) and usu-
ally does not interfere with visual acuity and is usually reversible, but 
can be associated with advanced retinopathy [44]. Retinal changes were 
also assessed in randomized participants by three studies where no ev-
idence for differences to placebo was detected, however, Leary et al., 
2009 reported a mild decrease in macular sensitivity which resolved 
spontaneously [28,39,40]. Although ophthalmic adverse events caused 
by tafenoquine appear mild, they should not be dismissed because 
conclusive data has yet to be developed. Notably the 4-aminoquinoline 
Table 6 
Overview of all adverse events displayed as number per 100 participants.   
Study Shanks 2001 Hale 2003 Walsh 2004 Leary 2009 Nasveld 2010 Stoute 2017 McCarthy 
2018  
participants for safety 
analysis (n) 
235 513 205 120.00 654 306 16  
Analysis based on mITT mITT mITT mITT mITT ITT ITT 
placebo AE n = 60/61; 
98.4% 
n = 91/94; 
96.8% 
n = 105/101; 
104% 
n = 61/39; 
156.4% 
NA n = 251/101; 
248.5% 
n = 22/4; 
550% 
serious AE n = 2/61; 
3.3% 
n = 1/94; 
1.1% 
n = 7/101; 
6.9% 
n = 3/39; 
7.7% 
NA n = 5/101; 5% n = 0/4; 0% 
related serious AE n = 0/61; 0% n = 0/94; 0% NR n = 0/39; 0% NA NR n = 0/4; 0% 
discontinued n = 7/61; 
11.5% 
NR n = 9/101; 
8.9% 
n = 4/39; 
10.3% 
NA n = 2/101; 2% n = 0/4; 0% 
discontinued due to AE n = 0/61; 0% n = 3/94; 
3.2% 
n = 0/101; 0% n = 2/39; 
5.1% 
NA n = 0/101; 0% n = 0/4; 0% 
250 mg mefloquine 
(weekly) 
AE NA n = 34/46; 
73.9% 
NA NA n = 328/162; 
202.5% 
n = 293/101; 
290.1% 
NA 
serious AE NA n = 0/46; 0% NA NA NR n = 2/101; 2% NA 
related serious AE NA n = 0/46; 0% NA NA NR NR NA 
discontinued NA NR NA NA n = 9/162; 
5.6% 
n = 2/101; 2% NA 
discontinued due to AE NA n = 0/46; 0% NA NA n = 3/162; 
1.9% 
n = 0/101; 0% NA 
400 mg tafenoquine 
(monthly) 
AE NA NA n = 148/104; 
142.3% 
NA NA NA NA 
serious AE NA NA n = 1/104; 1% NA NA NA NA 
related serious AE NA NA NR NA NA NA NA 
discontinued NA NA n = 8/104; 
7.7% 
NA NA NA NA 
discontinued due to AE NA NA n = 0/104; 0% NA NA NA NA 
200 mg tafenoquine 
(weekly) 
AE n = 77/55; 
140% 
n = 102/93; 
109.7% 
NA n = 113/81; 
139.5% 
n = 1043/492; 
212% 
n = 319/104; 
306.7% 
n = 25/12; 
208.3% 
serious AE n = 1/55; 
1.8% 
n = 2/93; 
2.2% 
NA n = 8/81; 
9.9% 
NR n = 10/104; 
9.6% 
n = 0/12; 0% 
related serious AE n = 0/55; 0% n = 0/93; 0% NA n = 1/81; 
1.2% 
NR NR n = 0/12; 0% 
discontinued n = 14/55; 
25.5% 
NR NA n = 9/81; 
11.1% 
n = 30/492; 
6.1% 
n = 2/104; 
1.9% 
n = 0/12; 0% 
discontinued due to AE n = 1/55; 
1.8% 
n = 9/93; 
9.7% 
NA n = 6/81; 
7.4% 
n = 12/492; 
2.4% 
n = 0/104; 0% n = 0/12; 0% 
400 mg tafenoquine 
(weekly) 
AE n = 88/59; 
149.2% 
NA NA NA NA NA NA 
serious AE n = 2/59; 
3.4% 
NA NA NA NA NA NA 
related serious AE n = 0/59; 0% NA NA NA NA NA NA 
discontinued n = 12/59; 
20.3% 
NA NA NA NA NA NA 
discontinued due to AE n = 0/59; 0% NA NA NA NA NA NA  
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Table 7 
Laboratory adverse events.   
Abnormal haemoglobin and 
haemolysis parameters 
Bilirubin Liver enzymes Kidney parameters methaemoglobin 
Shanks 
2001 
Shanks et al., 2001 recorded 
haemolytic events in two 
subjects; however, their G6PD 
status had been incorrectly 
determined identified during 
screening. 
NR NR NR A mean plateau concentration 
for weekly 200 mg 
tafenoquine of 2.5% ± 1.6% 
(SD) and for weekly 400 mg of 
4.5% ± 2.5% (SD) was 
reported. 
Hale 2003 Decreased haemoglobin cases 
(<8.0 g/dl): 
•placebo: 1/94 (1.06%) 
•tafenoquine 25 mg: 2/93 
(2.2%) 
•tafenoquine 50 mg: 2/93 
(2.2%) 
•tafenoquine 200 mg: 3/93 
(3.2%) 
NR elevated ALT levels (61.9–193 
U/L 
•placebo: 2/94 (2.1%), 
•tafenoquine 25 mg: 4/93 
(4.3%) 
•tafenoquine 50 mg: 4/93 
(4.3%) 
•tafenoquine 100 mg: 7/94 
(7.4%) 
•tafenoquine 200 mg: 6/93 
(6.5%) 
All elevated ALT levels were not 
dose- or weight-related. 
According to the study authors: 
“Nearly every subject, 
irrespective of study arm, 
experienced a notable, 
predominantly mild elevation 
in ALT level from baseline to 
week 4 that progressively 
diminished […] to the end 
point. Subjects with abnormally 
elevated ALT levels improved 
and/or their ALT levels 





NR NR Elevated ALT levels (>70 U/L): 
•placebo: 5/101 (5.0%), 
tafenoquine 7/104 (6.7%) 
The highest ALT values were 
caused by a chronic hepatitis B 
infection. All elevated ALT 
levels were transient and not 
associated with symptoms. 
Elevated serum creatinine: 
•tafenoquine 400 mg: 11/ 
104 (10.6%) 
•placebo 3/101 (3.0%) 
All elevated creatinine 
levels were transient, 
occurred between the 
loading and the first 
monthly dose and returned 




•tafenoquine 400 mg: 23/104 
(22.1%) 




Decrease in haemoglobin, 
haptoglobin and haematocrit: 
•Tafenoquine 200 mg: 1/81 
(1.2%). Resolved itself after 
tafenoquine withdrawal. 
A “higher incidence of mild 
reductions in haptoglobin 
(<85% baseline) in the 
tafenoquine group compared 
with the placebo group (47% 
versus 31%)” and a higher 
incidence of increased 
reticulocytes (≥150% 
baseline) in the tafenoquine 
group from week 3–12, but not 
in week 12–24′′ was reported. 
NR NR Elevated serum creatinine 
(≥26.6 μmol/L from 
baseline): 
•placebo: 1/32 (3.1%) 
•tafenoquine 200 mg: 3/70 
(4.3%) 
Those elevated serum 
creatinine values were 
interpreted as clinically 
important but were not 
associated with clinically 
significant decreases in 
GFR. 
Non-inferiority was found 
between tafenoquine 200 





Decreased haematocrit cases: 
•mefloquine: 23/162 (14.2%) 
•tafenoquine 200 mg: 98/492 
(20.0%) with two (0.4%) 
clinically significant cases 
(<85% of the lower limit of 
normal range) 
Increased bilirubin (>2 
μmol/L above from the 
baseline) 
•tafenoquine 200 mg: 49/ 
492 (10.0%) 
•mefloquine: 5/162 (3.1%) 
clinically significant 
increased bilirubin (>150% 
of the upper limit of normal 
ranges) 
•tafenoquine 200 mg: 13/ 
492 (2.6%) 
•mefloquine: 1/162 (0.6%) 
NR elevated serum creatinine 
(>125% baseline value) 








(continued on next page) 
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called chloroquine is known to cause a vortex keratopathy which can 
result in irreversible retinopathy and even progression after drug 
cessation [44]. It is advisable to avoid prolonged tafenoquine 
co-medication with other vortex keratopathy-causing drugs such as 
amiodarone. Ophthalmological examinations might be considered 
before, during and/or after tafenoquine intake for lengthy periods of 
several months, especially if additional co-factors like already existing 
visual disturbances and/or monocular vision is present. For a definitive 
conclusion, ongoing evaluation is indicated. 
No evidence for changes in nervous system or psychiatric AE were 
observed in the analysed trials compared to other treatment arms or 
placebo. Some events such as headache were reported more often in 
placebo recipients (Fig. 9) [28,29]. The molecular structures of prima-
quine and tafenoquine appear to eliminate the severe irreversible 
neurotoxicity observed in rhesus monkeys with other 8-aminoquino-
lines, specifically those having less than 4 methyl groups separating 
the primary and terminal amines of the aliphatic side chain [9,45]. 
Tafenoquine studies with rhesus monkeys showed no neurological signs 
that had been reported with those other 8-aminoquinolines at compa-
rable dosages [9]. Furthermore, a tafenoquine study in rats showed, that 
other adverse events than neurotoxicity were dose-limiting [46]. 
Nonetheless, unspecified 8-aminoquinoline neurotoxicity may occur in 
patients having pre-existing nervous system or psychiatric disorders. 
Such patients have been excluded from trials of tafenoquine and regu-
lators express caution regarding exposing them to tafenoquine (Ap-
pendix B) [9]. 
Quinolines and structurally related antimalarial drugs are known to 
have clinically relevant cardiovascular effects due to delay in ventricular 
depolarisation or QT prolongation [47]. No cardiac disorders were re-
ported in our systematic review, and a recent publication that focused on 
QTc changes after single dose tafenoquine, detected no clinically 
meaningful effect on cardiac repolarization [48]. 
Several instances of diminished haemoglobin in G6PD-normal par-
ticipants were reported, but only two cases of acute haemolytic anaemia 
occurred in G6PD-deficient subjects incorrectly identified as normal 
[38]. As is the case with other 8-aminoquinolines [19], G6PD screening 
is required to prevent potentially serious harm. In 2017, a single dose 
study showed that tafenoquine had similar haemolytic effects compared 
to 14 days of 15 mg primaquine base daily in healthy female volunteers 
heterozygous for mildly sensitive Mahidol variant of G6PD deficiency 
[49]. 
Clinically relevant elevation of bilirubin often occurred in tafeno-
quine recipients but was not more frequent than the same in those 
receiving placebo [33,37]. Elevated bilirubin levels can have several 
origins (e.g. haemolysis). However, no evidence for differences between 
study groups in liver enzymes or other haemolytic parameters were 
detected. The transient elevation of ALT, haemoglobin, and white blood 
cell (WBC) counts in all arms, reported by Hale et al., 2003, were 
interpreted as a result of the radical cure regimen at the beginning of the 
study [33]. The same conclusion might be made for the more common 
transient reduction of haptoglobin and increased reticulocytes reported 
in tafenoquine arms by Leary et al., 2009. However, those transient 
blood parameters might also be due to the destruction of naturally 
G6PD-diminished senescent erythrocytes by tafenoquine [50]. 
Other laboratory parameters that showed a trend for abnormal 
values in tafenoquine groups were serum creatinine and meth-
aemoglobin, but no evidence for differences to other study groups were 
reported. Creatinine levels are a fairly insensitive marker and in drug 
trials, cystatin c may serve as a more appropriate, highly sensitive 
marker of early renal dysfunction in future studies [51]. Tafenoquine, 
like all 8-aminoquinolines evaluated at therapeutic doses, causes 
methaemoglobin levels to rise slightly or moderately (typically 2–8% of 
Hb). This is of minor concern in normally dosed patients, however, an 
overdosage could lead to clinically relevant methaemoglobin concen-
trations (>20%) [52,53]. Even though serum creatinine changes were 
observed, Leary et al., 2009 showed by direct measuring of GFR, that 
renal functions were not impaired [28]. 
Another antimalarial drug, mefloquine, is known to attain higher 
plasma levels in female subjects compared to males. It has been con-
jectured that this may explain the higher incidence of mefloquine 
associated adverse events in women [54,55]. Conclusive data for sex 
differences in plasma drug levels during prolonged tafenoquine expo-
sure are unavailable because most tafenoquine studies have been 
dominated by male subjects. However, Hale et al., 2003 detected evi-
dence for an interaction between treatment efficacy and body weight (P 
< 0.001), which could play an incidental role in sex differences, should 
those be observed. A single dose tafenoquine safety study reported more 
adverse events in female participants, however a review including 6 
single-dose tafenoquine studies concerning population pharmacoki-
netics concluded that sex, ethnicity, or age did not impact on safety [16, 
56]. Charles et al., 2007 analysed the population pharmacokinetics of 
the population from Nasveld et al., 2010 and concluded that measured 
tafenoquine concentrations in that study are not the primary predictor of 
tafenoquine tolerability. However, since the analysed population con-
sisted of homogenous military personal (Table 1) pharmacokinetics in 
overweight or underweight may still require dose adjustments [14]. A 
similar conclusion was published by Edstein et al., 2001, concerning a 
population of Thai soldiers [37]. 
This systematic review with meta-analysis combines data to estimate 
efficacy and adverse events/safety with more accuracy than a single 
study. However, there are limitations to consider, mainly several dif-
ferences in population characteristics, a limited population size for 
detecting rare adverse events, inclusion of healthy people only (Ap-
pendix B), low numbers of women, risk of bias, and differences in 
adverse events reporting (Table 4). 
The populations differed in ethnicity, nutritional status, culture, 
employment (e.g. military) stress levels (e.g. peacekeeping operation in 
East Timor [19]), tolerance of medications, semi-immunity, and varying 
degree of female/male ratios. This population heterogeneity makes it 
difficult to compare absolute numbers between single studies, especially 
for adverse events reporting [57]. The differences in study design be-
tween longitudinal trials and human challenge studies limit their 
comparability, since human challenge studies have fewer participants 
and a guaranteed exposure rate of 100%. 
Table 7 (continued )  
Abnormal haemoglobin and 
haemolysis parameters 




•tafenoquine 200 mg: 1/104 
(1.0%) 
NR NR NR NR 
McCarthy 
2018 
Decrease in haemoglobin: 
•tafenoquine 200 mg: 2/12 
(16.7%) 
Both cases were interpreted as 
not clinically significant and 
they resolved without 
treatment. 
Hyperbilirubinemia (29.0 
μmol/L) in one participant of 
the tafenoquine group, which 
resolved spontaneously. 
NR NR NR  
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The low portion of female participants restrict prediction of adverse 
events in women. It has already been described that mefloquine is 
associated more often with neuropsychological adverse events in 
women compared to men [58]. This would also explain the missing 
higher incidence of neuropsychological adverse events in all 3 RCT’s 
with mefloquine arms (female portion n = 303/1463; 20.7%). 
Since pregnant or breast-feeding women, children, G6PD-deficient, 
and those with psychiatric disorders, neurological disorders, abnormal 
laboratory results and/or clinical examinations were all excluded (App. 
B), the conclusion for safety and efficacy in this systematic review is 
restricted to the included participants and may not accurately or reliably 
apply to populations of travellers that may include these groups, unin-
tentionally or otherwise. The strengths of our meta-analysis are the in-
clusion of well conducted randomized studies, most with a low risk of 
bias, the stringent selection criteria used in our methodology and the 
thorough statistical analyses performed. 
5. Conclusion 
Between 1998 and 2018, nine randomized, controlled studies con-
cerning tafenoquine chemoprophylaxis efficacy and safety were pub-
lished. Our systematic review and meta-analysis of these studies 
indicates that weekly tafenoquine 200 mg regimens are well tolerated 
and effective as malaria chemoprophylaxis focusing primarily on Plas-
modium falciparum but also on Plasmodium vivax. An increased risk of 
gastrointestinal adverse events in the tafenoquine arms were reported by 
three studies, and one study detected a significant increase in reversible 
vortex keratography with 6 months of dosing. Most studies to date have 
been done in young adult and predominantly male populations. Further 
research is indicated on the use of tafenoquine in far more diverse 
traveller populations in order to detect rarer adverse events, sex dif-
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